Form 4: Revolution Medicines' General Counsel Sells Shares Under 10b5-1 Trading Plan

Jeff Cislini, General Counsel of Revolution Medicines, sold a total of 1,500 shares of common stock on May 21, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 21, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 1,500 shares of the company's common stock.
• The sales were executed under a 10b5-1 trading plan adopted on March 27, 2023.
• 700 shares were sold at a weighted average price of $38.6657, and 800 shares were sold at a weighted average price of $39.5061.
• Following the transactions, Cislini directly owns 52,874 shares of Revolution Medicines common stock, which includes 48,972 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to insider trading. The sales were conducted under a pre-arranged 10b5-1 trading plan, suggesting no immediate negative sentiment. It's a neutral event.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's perspective on the company's prospects. Sales under a 10b5-1 plan are generally less concerning as they are pre-arranged.

Stakeholder Impact

• The stock sale by a key executive could cause short term uncertainty among shareholders.

Key Dates